Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Darbepoetin (Aranesp) -- a long-acting erythropoietin

Article Abstract:

The FDA has approved the drug Aranesp for treating anemia caused by chronic kidney disease. This drug stimulates the production of red blood cells. It is more convenient than Epogen or Procrit because it can be given once a week rather than two or three times a week. Some studies have shown it to be effective when given every two or three weeks.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2001
United States, Anemia, Amgen Inc., AMGN, Aranesp (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Zoledronate (Zometa)

Article Abstract:

The FDA has approved the drug Zometa in an intravenous form for treating cancer patients who have increased calcium in their blood. This drug belongs to a group of drugs called bisphosphonates. It has also been tested in patients with Paget's disease of bone and in postmenopausal women with osteoporosis.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2001
Hypercalcemia, Zometa (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Gleevec (STI-571) for chronic myeloid leukemia

Article Abstract:

The FDA has approved Gleevec for the treatment of chronic myeloid leukemia. The drug is a tyrosine kinase inhibitor that specifically inhibits the Bcr-Abl protein. Many patients who take the drug go into remission.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 2001
Chronic myeloid leukemia, Gleevec (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Pharmaceutical industry, Product/Service Evaluation, Product information, Drug therapy, Switzerland, Novartis AG, NVTSY
Similar abstracts:
  • Abstracts: Telomerase and the aging cell: implications for human health. The Ethics of Embryonic Stem Cells--Now and Forever, Cells Without End
  • Abstracts: Decreased erythropoietin response in patients with the anemia of cancer. Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation
  • Abstracts: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. Oral contraceptive and the risk of myocardial infarction
  • Abstracts: Lack of Fas antagonism by Met in human fatty liver disease. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
  • Abstracts: Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.